Susan G. Komen®, the world’s leading breast cancer organization, named Geoffrey M. Wahl, PhD, and Norman Wolmark, MD, FACS, FRCSC, two leading breast cancer researchers, as recipients of this year’s Brinker Awards, Komen’s highest scientific honor.
Susan G. Komen® is awarding $21.7 million to fund 48 new research projects at 26 distinguished academic medical institutions in the U.S. that are focused on improving patient outcomes – particularly for people with the most aggressive breast cancers, or who have experienced a recurrence or metastasis.
Findings from a recent population based cohort study published online in JAMA Oncology show that Black women diagnosed with breast cancer who also have central obesity, which means excess body fat in the abdominal area, were more likely to die from breast cancer or any other cause than similar women who didn’t have central obesity.
The outlook for patients diagnosed with breast cancer has been changing for the better over time thanks to surgical advances, clinical trials & a more personalized treatment approach. Dr. Lindsay Potdevin, surgical oncologist at Rutgers Cancer Institute of New Jersey, shares how these advances are improving the lives of patients.
Department of Radiology Chair Elizabeth Morris, with the UC Davis Comprehensive Cancer Center, was awarded a Susan G. Komen® grant to develop artificial intelligence models to predict breast cancer risk at a more personalized level
Atlantic Health System Cancer Care will continue its tradition of world-class medical education by hosting its 2021 Annual Review in Oncology Virtual Symposium. The symposium, held via Microsoft Teams with free registration, will take place Saturday, June 26, 2021, from 8 a.m. to 12:30 p.m. ET. Distinguished faculty from some of the nation’s leading cancer centers will summarize the latest advances in six areas of oncology, as presented at the just-completed ASCO conference—the world’s premiere meeting for cancer care professionals and researchers.
The research utilizes the body’s natural killer cells, part of the human immune system, to target breast cancer tumor cells. The triggers are fusion proteins developed by Clemson University researchers that link the two together. The research is a novel approach to developing breast cancer-specific immunotherapy.
Researchers at Rutgers Cancer Institute of New Jersey and Rutgers New Jersey Medical School (NJMS) recently discovered a phage display-based approach to halt tumor growth that could be used to treat triple-negative breast cancer – considered the most aggressive type of breast cancer. The findings were published online in the scientific journal eLife.
New research in the February 2021 issue of JNCCN examined body mass index (BMI) data for people with HER2-positive early breast cancer, and found a 5% weight loss in patients over two years in was associated with worse outcomes. Weight gain over the same time period did not affect survival rates.
Atlantic Health System Cancer Care today announced that fellowship-trained medical oncologist, Shilpi Gupta, MD, has joined Morristown Medical Center’s comprehensive breast health program where her focus is breast oncology and research. Dr. Gupta is on staff at Atlantic Hematology Oncology at the hospital’s Carol G. Simon Cancer Center.
A new type of breast cancer drug can help halt progression of disease and is not toxic, according to phase 1 clinical trials.
Genetic modifier HDAC6 was found to control tumor growth and halt metastasis in triple-negative breast cancer in vivo, according to a new study published in the journal Cancer Research by investigators at the GW Cancer Center.